Evidence map›Paper›PMID 40103792›Full record

ArticleFrontiers in medicine2025

Detection of potential complications in cancer survivors after chemotherapy and development of a regional care network: the PASCA feasibility study.

Romain Buono, Olivia Pérol, Meyssane Djebali, Mélodie Borja, Alicia Abadie, Stéphane Morisset, Anne-Sophie Michallet, Aude Fléchon, Helen Boyle, Emmanuelle Nicolas-Virelizier and 8 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Romain BuonoDepartment of Prevention, Cancer and Environment, Léon Bérard Cancer Center, Lyon, France.
Olivia PérolDepartment of Prevention, Cancer and Environment, Léon Bérard Cancer Center, Lyon, France.
Meyssane DjebaliDepartment of Prevention, Cancer and Environment, Léon Bérard Cancer Center, Lyon, France.
Mélodie BorjaDepartment of Prevention, Cancer and Environment, Léon Bérard Cancer Center, Lyon, France.
Alicia AbadieDepartment of Prevention, Cancer and Environment, Léon Bérard Cancer Center, Lyon, France.
Stéphane MorissetDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Anne-Sophie MichalletDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Aude FléchonDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Helen BoyleDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Emmanuelle Nicolas-VirelizierDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Philippe ReyDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Yann GuillerminDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Souad AssaadDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Amine BelhabriDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Laure LebrasDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Jean-Yves BlayDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Béatrice FerversDepartment of Prevention, Cancer and Environment, Léon Bérard Cancer Center, Lyon, France.
Mauricette MichalletDepartment of Prevention, Cancer and Environment, Léon Bérard Cancer Center, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complications are often poorly identified and managed in cancer survivors after treatment and restoring their initial quality of life remains a challenge, particularly in a context of unequal access to care nationwide. The PASCA "Parcours de Santé au cours du Cancer [in English: healthcare pathways with cancer]" feasibility study was conducted in the Léon Bérard Comprehensive Cancer Center (Lyon, France) to assess the feasibility of a complications detection program, in cancer survivors who have received intensive chemotherapy. An initial network of physicians and healthcare professionals was also set up to facilitate medical referrals after detection. The study had a high recruitment rate (83.8%) and an adherence rate of 43%. In our analysis population (

Indexed as

cancer survivorscomplication detectionfeasibility studyhematological malignancytesticular germ cell tumors

Identifiers

PMID40103792
PMCPMC11914117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.